CN109475614A - 生产用于癌症免疫疗法的dna疫苗的方法 - Google Patents

生产用于癌症免疫疗法的dna疫苗的方法 Download PDF

Info

Publication number
CN109475614A
CN109475614A CN201780043297.1A CN201780043297A CN109475614A CN 109475614 A CN109475614 A CN 109475614A CN 201780043297 A CN201780043297 A CN 201780043297A CN 109475614 A CN109475614 A CN 109475614A
Authority
CN
China
Prior art keywords
leu
ser
val
antigen
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780043297.1A
Other languages
English (en)
Chinese (zh)
Inventor
海因茨·卢本奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nec Orkmnet
Original Assignee
Si Meng Limited-Liability Co Of Wanke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Si Meng Limited-Liability Co Of Wanke filed Critical Si Meng Limited-Liability Co Of Wanke
Publication of CN109475614A publication Critical patent/CN109475614A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780043297.1A 2016-07-13 2017-07-12 生产用于癌症免疫疗法的dna疫苗的方法 Pending CN109475614A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16001550.9 2016-07-13
EP16001550 2016-07-13
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
CN109475614A true CN109475614A (zh) 2019-03-15

Family

ID=56418345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043297.1A Pending CN109475614A (zh) 2016-07-13 2017-07-12 生产用于癌症免疫疗法的dna疫苗的方法

Country Status (13)

Country Link
US (2) US10821163B2 (https=)
EP (1) EP3484503A1 (https=)
JP (2) JP7098599B2 (https=)
KR (3) KR20190027834A (https=)
CN (1) CN109475614A (https=)
AU (1) AU2017295004B2 (https=)
BR (1) BR112019000657A2 (https=)
CA (1) CA3028549A1 (https=)
IL (1) IL263568A (https=)
MX (1) MX2019000415A (https=)
RU (1) RU2019100079A (https=)
SG (1) SG11201811258UA (https=)
WO (1) WO2018011289A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149982A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
JP7598315B2 (ja) * 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20230121528A1 (en) 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
WO2024005122A1 (ja) * 2022-06-30 2024-01-04 株式会社島津製作所 微生物の分析の準備方法、および、微生物の分析方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104066834A (zh) * 2011-12-22 2014-09-24 万科斯蒙股份有限公司 产生高产的沙门氏菌减毒菌株的方法
CN104519908A (zh) * 2012-07-05 2015-04-15 万科斯蒙股份有限公司 用于胰腺癌患者的dna疫苗
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2015090584A1 (en) * 2013-12-18 2015-06-25 Vaximm Gmbh Mafinex-Technologiezentrum Novel msln targeting dna vaccine for cancer immunotherapy
CN105246496A (zh) * 2013-04-25 2016-01-13 万科斯蒙股份有限公司 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3892295T3 (pl) * 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104066834A (zh) * 2011-12-22 2014-09-24 万科斯蒙股份有限公司 产生高产的沙门氏菌减毒菌株的方法
US20140349274A1 (en) * 2011-12-22 2014-11-27 Vaximm Ag Method for Producing High Yield Attenuated Salmonella Strains
CN104519908A (zh) * 2012-07-05 2015-04-15 万科斯蒙股份有限公司 用于胰腺癌患者的dna疫苗
CN105246496A (zh) * 2013-04-25 2016-01-13 万科斯蒙股份有限公司 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体
WO2015090584A1 (en) * 2013-12-18 2015-06-25 Vaximm Gmbh Mafinex-Technologiezentrum Novel msln targeting dna vaccine for cancer immunotherapy
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine

Also Published As

Publication number Publication date
AU2017295004B2 (en) 2020-08-13
EP3484503A1 (en) 2019-05-22
AU2017295004A1 (en) 2019-01-03
RU2019100079A (ru) 2020-08-13
US11590215B2 (en) 2023-02-28
KR20190027834A (ko) 2019-03-15
WO2018011289A1 (en) 2018-01-18
JP2022097591A (ja) 2022-06-30
JP2019521154A (ja) 2019-07-25
BR112019000657A2 (pt) 2019-04-24
JP7098599B2 (ja) 2022-07-11
US10821163B2 (en) 2020-11-03
US20190183996A1 (en) 2019-06-20
IL263568A (en) 2019-01-31
KR20230079514A (ko) 2023-06-07
CA3028549A1 (en) 2018-01-18
SG11201811258UA (en) 2019-01-30
US20220072112A1 (en) 2022-03-10
MX2019000415A (es) 2019-03-28
KR20260047288A (ko) 2026-04-07

Similar Documents

Publication Publication Date Title
AU2017295004B2 (en) Process for the production of a DNA vaccine for cancer immunotherapy
KR102090612B1 (ko) 췌장암 환자용 dna 백신
CN107995868B (zh) 用于联合治疗的vegfr-2靶向dna疫苗
KR20190125481A (ko) 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신
JP2024167172A (ja) 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
AU2018222777B9 (en) Novel VEGFR-2 targeting immunotherapy approach
CN109906087A (zh) 用于联合治疗的wt1靶向dna疫苗
KR20220161444A (ko) 새로운 살모넬라-기반의 코로나바이러스 백신
KR20220128638A (ko) 항생제와 조합되는 살모넬라-기반의 dna 백신
Chen et al. Avirulent ME49Δ gra5 Protecting Hosts Against Toxoplasma gondii Infection and Breast Tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220523

Address after: Oslo, Norway

Applicant after: NEC orkmnet

Address before: Basel, Switzerland

Applicant before: VAXIMM AG